Trials / Completed
CompletedNCT01882491
Safety and Biologic Activity Study of Gevokizumab to Treat Erosive Osteoarthritis of the Hand
A Phase 2 Proof-of-concept Study of Gevokizumab in Subjects With Inflammatory Erosive Osteoarthritis of the Hand
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 91 (actual)
- Sponsor
- XOMA (US) LLC · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this proof-of-concept study is to determine whether gevokizumab is effective in the treatment of inflammatory erosive osteoarthritis of the hand.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Placebo | Solution for subcutaneous injection |
| DRUG | gevokizumab | Solution for subcutaneous injection |
Timeline
- Start date
- 2013-05-01
- Primary completion
- 2014-02-01
- Completion
- 2014-02-01
- First posted
- 2013-06-20
- Last updated
- 2014-03-04
Locations
23 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01882491. Inclusion in this directory is not an endorsement.